Fusion Antibodies plc
FAB.L · LSE
9/30/2025 | 3/31/2025 | 9/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Market Cap | £19,812 | £5,928 | £2,333 | £1,965 |
| - Cash | £252 | £359 | £439 | £1,199 |
| + Debt | £388 | £20 | £32 | £43 |
| Enterprise Value | £19,948 | £5,589 | £1,926 | £809 |
| Revenue | £838 | £758 | £1,207 | £595 |
| % Growth | 10.6% | -37.2% | 102.9% | – |
| Gross Profit | £185 | £105 | £325 | -£56 |
| % Margin | 22.1% | 13.9% | 26.9% | -9.4% |
| EBITDA | -£476 | -£888 | -£736 | -£773 |
| % Margin | -56.8% | -117.2% | -61% | -129.9% |
| Net Income | -£512 | -£955 | -£758 | -£869 |
| % Margin | -61.1% | -126% | -62.8% | -146.1% |
| EPS Diluted | -0.005 | -0.01 | -0.014 | -0.017 |
| % Growth | 54.5% | 27.2% | 20% | – |
| Operating Cash Flow | -£575 | -£612 | -£752 | -£419 |
| Capital Expenditures | -£60 | -£10 | £0 | -£2 |
| Free Cash Flow | -£635 | -£622 | -£752 | -£421 |